Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...

Transverse tubules (T-tubules) play a significant role in muscle contraction. However, the underlying mechanism of their ...

Arrowhead Pharmaceuticals said Tuesday that its gene-silencing drug candidate nearly doubled four-month weight loss ...

RNA drugs are a new type of medicine that treat disease by influencing how cells use genetic information, rather than by ...

Arrowhead Pharmaceutical’s investigational RNA interference (RNAi) obesity candidate in combination with Eli Lilly’s Zepbound ...

Shares of Arrowhead Pharmaceuticals rose after the company reported positive interim data from two Phase 1/2 trials for obesity treatments. The stock was up 17%, at $74.61, late Tuesday morning and ...

Arrowhead Pharmaceuticals today announced interim results from two Phase I/IIa clinical trials of ARO-INHBE and ARO-ALK7, the ...

Arrowhead Pharmaceuticals reported early trial data showing notable reductions in body, liver, and visceral fat from two experimental obesity drugs, with more results expected in 2026.

Arrowhead Pharmaceuticals, Inc. today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics being ...

Arrowhead Pharmaceuticals recently announced that Health Canada issued a Notice of Compliance for REDEMPLO (plozasiran) as an ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.